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 INTRODUCTION 
Sodium is the predominant cation of the extracellular compartment. It is the major 
contributing electrolye to serum osmolality. Hyponatremia is serum 
sodium<135meq/L. The prevalence of hyponatremia in general population is 4-7% 
whereas upto 30-40% of hospitalised patients have some degree of hyponatremia 
making it the most common electrolyte disorder(1,2). Since clinically symptomatic 
hyponatremia is rare, hyponatremia is frequently underdiagnosed.  
In patients with cirrhosis hyponatremia is common due to disproportionate fluid 
retention in excess of sodium retention. Patients are hypervolemic but with reduced 
intravascular volume. Since hyponatremia is the outcome of compensatory 
mechanisms, the degree of hyponatremia can estimate the severity of underlying 
pathology. Recent studies show that sodium levels before liver transplantation 
predicted the outcome and development of neurological complications after 
transplant. Studying the importance of hyponatremia in cirrhosis can give an 
insight into usefulness of treating hyponatremia in cirrhotic patients in future. 
Hence we conducted this study in 100 cirrhosis patients in our hospital to find the 
prevalence of hyponatremia and its association with complications. 
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AIMS AND OBJECTIVES: 
1. To study the prevalence of hyponatremia in cirrhotic patients 
2. To study the association between hyponatremia and complications of 
cirrhosis and its correlation with severity of complications. 
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REVIEW OF LITERATURE 
             The major constituent of human body is  water, which contributes to about  
50% of body weight of average  adult woman & 60% in  men. Since fat 
contains less  water,  an obese person tends  to  have  less  amount  of  body 
water. About 55 – 75% of total body water  is  intracellular and  25 – 45% is 
extracellular. The  ECF  is  further  subdivided  into Intravascular (plasma)  
and  extravascular ( interstitial)  spaces in the ratio  of 1:3(3). 
                        The distribution of fluid across these spaces is determined by 
starling forces. According to Starling‟s  hypothesis,  the fluid movement 
across capillary is determined by the hydrostatic and osmotic pressure 
differences between intravascular and extravascular compartment. 
                           
                                         Figure1 – Starling hypothesis 
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The  plasma ultrafiltrate  moves into the extravascular  space when  the 
transcapillary  hydraulic  pressure gradient exceeds the oncotic  pressure gradient. 
The  return  of  fluid  into  the intravascular  compartment occurs via  
lymphatics(4). 
                         Osmolality  of  a  fluid  is  defined  as the solute  or  particle 
concentration  of a fluid.  It  is  expressed  as  milliosmoles  per kg of  water. 
                       The  major  intacellular  anions  are  phosphate, sulphate  and  
protein  and  extracellular  anions  are  chloride and  bicarbonate. The  major  
intracellular  cation is potassium and  extracellular  cation  is  sodium. 
   Table 1 –Composition of electrolytes in body fluids(5) 
 
Electrolytes(mEq/L) ECF ICF 
Sodium 142 10 
Potassium 4.3 140 
Chloride 104 2 
Bicarbonate 24 6 
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Figure 2 – Fluid composition of the body 
 
REGULATION  OF  WATER  BALANCE: 
                    The human body  fluid  osmolality  ranges  normally between  280 and 
295 mosm/kg. It is maintained  within  this  narrow range by  the  following  
mechanisms(6), 
                 1). Thirst  mechanism 
                 2). Vasopressin  secretion 
                 3). Renal  handling  of  sodium  & water 
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1). THIRST  MECHANISM: 
                   Drinking or fluid intake  is regulated by  plasma osmolality  and  ECF 
volume.  Water intake  is increased  by increase  in  effective osmotic pressure of  
the  plasma,  by decrease in  ECF  volume , by  psychological  and  other  factors. 
             HYPERTONICITY                                 HYPOVOLEMIA 
 
          OSMORECEPTORS                              BARORECEPTORS 
                                                                                   ANGIOTENSIN II 
                HYPOTHALAMUS 
    
      
             Osmolality acts  via osmoreceptors, receptors that  sense the osmolality  of  
the  body fluids that are located in the  anterior  hypothalamus. 
 Decrease in  ECF volume also stimulates  thirst  by   a  pathway independent  of  
that  mediating  thirst  in  response  to increase in plasma osmolality.  The  effect of  
hypovolemia  on  thirst  is mediated  in  part  via  the  renin - angiotensin  system.       
Hypovolemia stimulates renin angiotensin axis. The  Angiotensin II acts on the 
THIRST  
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subfornical  organ in  the diencephalon , to  stimulate the neural areas  that regulate  
thirst. There is also  evidence suggesting  that  it acts  on  organum  vasculosum of  
the  lamina  terminalis (OVLT)  as well. These  areas are located  outside the  
blood  brain  barrier and  highly  permeable.  
Baroreceptors in  the heart & blood vessels also have a role on thirst  control. 
When patients are in altered sensorium or when the disease process damages the 
thirst centre directly, fluid intake is reduced and this results in hypovolemia.                     
2). ROLE  OF  VASOPRESSIN : 
                       Vasopressin or anti- diuretic  hormone (ADH)  is synthesized in  the  
cell bodies of the  magnocellular neurons   in  the supraoptic and paraventricular  
nuclei and transported down the axons of  these neurons  to their endings  in  the 
posterior lobe, where they are secreted  in response  to electrical activity in the 
nerve endings. 
                            It is synthesized  as precursor  molecule,   Prepro pressophysin, 
contains a 19 – amino acid and  residue leader  sequence followed by arginine  
vasopressin, neurophysin  and  a  glycopeptide.  Prepro pressophysin  is  
synthesized  in  the ribosomes of cell bodies of  neurons. The  secretory granules 
are called herring bodies.  They  are  secreted into circulation by means of  
exocytosis  involving  calcium. 
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VASOPRESSIN RECEPTORS :  
                          There are three kinds of vasopressin receptors : V1A , V1B ,V2 . V1a 
recptors mediate vasoconstriction, myocardial hypertrophy. It also plays a role in 
glycogenolysis. V 1b  receptors regulate the release of ACTH in the anterior 
pituitary. V2 receptors mediate water reabsorption in the kidneys. They are also 
involved in release of von-willebrand factor(9). 
ACTION OF VASOPRESSIN :  
                          ADH acts on the V2 receptors in  the  basolateral  membrane of  
cells in  the medullary and cortical  collecting  tubules . Normally apical membrane 
is impermeable  to  water  in the absence  of  ADH , but  basolateral  membrane is  
freely  permeable . Simple  diffusion of  water  is  augmented  by  the  presence  of  
water  channels  called  AQUAPORINS . 
                 Aquaporins  1,2,3  are present in  the kidney , aquaporin 4  is found in  
the brain and aquaporin 5  in  the salivary  glands.  The  vasopressin responsive 
water  channel  in  the  collecting  duct  is  Aquaporin- 2. The action of  ADH  at  
V2 receptors activates  Adenyl cyclase and cAMP  is formed.  This  causes  
translocation  of  aquaporin-2  containing  vesicles  to  the  apical membrane. 
Thereby  the apical  membrane  is  rendered  permeable  to  water. (figure 3) 
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               In the absence of ADH , the apical  membranes of  the cells in the 
collecting  tubules are impermeable  to  water. Large  volumes of hypotonic urine 
will  be produced. In the presence  of  ADH, water is reabsorbed in the collecting 
duct. The  urine  becomes  hypertonic and  its  volume  decreases.  This results in 
increased retention of water compared to solutes which causes lowering of 
osmolarity. In the presence of ADH i.e, at  maximum levels, less  than 1% of  the  
filtered water is  excreted. 
                             V1A receptors mediate the vasoconstrictor effect of ADH. But 
large doses are required to increase  blood pressure as it also acts on the brain to 
decrease cardiac output.  V1A receptors  are also found  in liver, where ADH causes 
glycogenolysis. The V1B receptors  are unique to pituitary, where they regulate 
ACTH secretion from the corticotrophs. 
METABOLISM : 
                    The half life of AVP in the circulation is only 30 minutes ,thus 
changes in the ECF volume or circulating osmolality can rapidly affect water 
metabolism . 
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          Figure 3 – Mechanism of action of vasopressin 
                   
                       Figure 4 – Regulation of vasopressin secretion 
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REGULATION OF VASOPRESSIN SECRETION:  
OSMOTIC STIMULI:  
                 Vasopressin stimulation occurs when the plasma osmolality is more than 
285 mosm/kg . Further,there is a linear relationship between osmolality and 
circulating vasopressin. Significant changes occur even the osmolality is changed 
as  little as 1% . Vasopressin secretion is controlled by a delicate feedback 
mechanism (figure 4)that aims to maintain plasma osmolality in physiological 
range(10).  
VOLUME EFFECTS: 
                      The amount of vasopressin secretion is inversely related to the rate of 
discharge in afferents from stretch receptors of vascular system . The increase in 
vasopressin secretion in response to decrease in effective arterial pressure is 
exponential rather than linear . 
                 There are also non-osmotic stimuli such as pain,emotion and exercise 
that cause increase in vasopressin secretion. Intake of alcohol causes decreases 
vasopressin secretion. Drugs like clofibrate, carbamazepine cause increased 
secretion of vasopressin.  
 
25 
 
3)RENAL HANDLING OF WATER AND SODIUM: 
                Normally ,180 L of fluid is filtered through the glomeruli each day , 
while the average daily urine volume is 1 L. 
                In the proximal tubule, 60-70% of water moves by passive transport 
along osmotic gradient due to active transport of solutes and isotonicity is 
maintained. The descending limb of loop of Henle is permeable to water, but the 
ascending limb is impermeable. The fluid becomes hypertonic in the descending 
limb and hypotonic to plasma in the ascending limb. Na
+
K
+
2Cl
- 
 cotransporter in 
the basolateral membrane is responsible for the transport of sodium from lumen to 
the cell(11). 
                The distal tubule is relatively impermeable to water and 5% of filtered 
water is removed here. The collecting duct under the influence of vasopressin as 
explained above reabsorbs further 10% of filtered water through Aquaporin2. 
                The concentrating mechanism depends on the maintainence of gradient 
of increasing osmolality along the medullary pyramids. The gradient is produced 
by the constant circulation of fluid and electrolytes across the loop of Henle that 
functions as countercurrent multipliers and  is maintained by the operation of 
vasarecta as countercurrent exchangers. 
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Figure 5 – Renal handling of water  
                 The operation of each loop of Henle as a countercurrent multiplier 
depends on the active transport of Na
+
 and Cl
-
 out of its thick ascending limb, and 
its contents equilibriate with the interstitium. But fluid containing 300mosm/kg of 
water is continuously entering from proximal tubule, so the gradient against which 
the Na
+
 and Cl
- 
are pumped is reduced and more enters the interstitium. 
                 This process continues repeatedly, and the end result is a gradient of 
osmolality from the top to the bottom of the Henle‟s loop. The osmotic gradient in 
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the medullary pyramids is maintained as the solutes remain in the pyramids 
primarily due to vasarecta operating as countercurrent exchangers(3). 
 
   Figure 6-Countercurrent multiplier and countercurrent exchanger 
                 
 The  daily solute load of our body can be excreted  in a urine volume as low as 
500ml with a concentration of 1400mosm/kg. If not for the countercurrent 
mechanism, action of vasopressin, the solutes will be excreted in a volume of about 
23L with a concentration of 30mosm/kg. 
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RENAL REGULATION OF Na
+
 EXCRETION: 
               In the kidneys, sodium is freely filtered in large amounts, but it is actively 
reabsorbed throughout the tubule except the thin loop of Henle. Out of the total 
96%-99% of the filtered Na
+
 65% is reabsorbed in proximal tubule and 25% in 
thick ascending loop of Henle. Through action of multiple mechanisms, the 
amount of Na
+
 excreted is adjusted according to daily intake to maintain normal 
sodium levels. Thus, urinary Na
+ 
output ranges from less than 1meq/d on a low salt 
diet to 400meq/d or more when dietary intake of Na
+
 is high.            
           
Figure 7 – Renal handling of sodium 
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Factors affecting Na
+
 reabsorption are, 
-Aldosterone and other adrenocortical hormones  
-Atrial natriuretic peptide and other natriuretic hormones 
-Rate of tubular secretion of H
+
 and K
+
  
 
     HYPONATREMIA 
         Sodium is the most abundant cation in the ECF and Na
+
 salts account for 
over 90% of the osmotically active solute in the plasma and interstitial fluid. 
Therefore, the amount of Na
+
 in the body is the prime determinant of ECF volume. 
         The normal serum sodium ranges from 135-145meq/L. 
Types of hyponatremia: 
 Hypovolemic hyponatremia 
 Hypervolemic hyponatremia 
 Euvolemic hyponatremia 
 Redistributive hyponatremia 
Pseudohyponatremia 
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Figure 8- Types of hyponatremia 
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HYPOVOLEMIC HYPONATREMIA: 
 It occurs as the result of decrease in total body water. Total body sodium 
decreases to a relatively greater extent. The ECF volume is decreased. It occurs 
due to following reasons. 
 Nonrenal loss: 
In these cases urine sodium is less than 20mM. It may be due excessive 
sweating, vomiting or loose stools, fluid leak into various serous cavities and 
also in burns, muscle injury, pancreatitis. 
 Cerebral salt-wasting syndrome: (13-15) 
Occurs in patients with CNS diseases such as meningitis, subarachnoid 
hemorrhage, head injury and surgeries. In contrast with SIADH, these 
patients respond to aggressive Na
+
 and Cl
- 
replacement. 
 Renal Loss 
In Acute or chronic renal insufficiency, there is impairment of excretion of 
solute free water due to renal malfunction. 
Salt-wasting nephropathies(16) may lead to hyponatremia when sodium intake is 
reduced due to impaired renal tubular function- typical causes include reflux 
nephropathy, interstitial nephropathies, post-obstructive uropathy, medullary cystic 
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disease, and the recovery phase of acute tubular necrosis. Urine Na
+
 concentration 
is typically>20mM 
HYPERVOLEMIC HYPONATREMIA: 
In hypervolemic hyponatremia,patients develop an increase in total body Na
+
-Cl
–
 
that is accompanied by a proportionately greater increase in total body water, 
leading to a reduced plasma Na
+
 concentration. It can be categorised into two 
according to urine sodium excretion .  
 Acute or chronic renal failure uniquely associated with an increase in urine 
Na
+
 concentration >20. 
 Sodium-avid edematous disorders are associated with decrease in urinary 
sodium excretion. Some of these disorders are nephrotic 
syndrome,congestive cardiac failure and cirrhosis.(17)  
The pathophysiology of hyponatremia  is similar in these conditions except that 
arterial filling and circulatory integrity are decreased due to the specific etiologic 
factors, e.g., cardiac dysfunction in CHF and peripheral vasodilation in 
cirrhosis(18). Urine Na
+
 concentration is typically very low, i.e., <10 mM, even 
after hydration with normal saline; this Na
+
-avid state may be obscured by diuretic 
therapy. The degree of hyponatremia provides an indirect index of the associated 
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neurohumoral activation and is an important prognostic indicator in hypervolemic 
hyponatremia. 
EUVOLEMIC HYPONATREMIA: 
In this case the patient clinically has no edema. It can occur due to severe 
hypothyroidism, secondary adrenal deficiency, pituitary disease and glucocorticoid 
deficiency. The most common cause of euvolemic hyponatremia is Syndrome of 
inappropriate antidiuretic hormone (SIADH). The generation of hyponatremia 
requires an intake of free water which is persistent even at serum osmolalities 
lower than the usual thirst threshold. There are 4 types of AVP secretion in 
SIADH. 
Table 2 –Types of AVP secretion 
Type A Unregulated erratic AVP secretion irrespective of serum 
osmolality 
Type B 
“reset osmostat” 
Patients with lower osmolality threshold 
Type C Failure of secretion of AVP at lower osmolality 
Type D Patients with an antidiuretic substance distinct from AVP 
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Serum uric acid is usually low(<4mg/dl) in patients with SIADH, due to 
suppressed proximal tubular transport in the setting of increased distal tubular 
water and electrolyte transport. But patients with hypovolemic hyponatremia are 
often hyperuricemic, due to shared activation of proximal tubular Na
+
Cl
- 
and urate 
transport. 
Table 3- Common causes of SIADH 
Pulmonary diseases Pneumonia, tuberculosis, pleural 
effusion, respiratory failure with 
positive pressure ventilation 
Malignant diseases Lung carcinomas(small-cell ca), 
gastrointestinal and oropharyngeal 
malignancies 
CNS diseases Tumours, subarachnoid hemorrhage, 
meningitis 
drugs Drugs that stimulate release of AVP or 
enhance its action, chlorpropamide, 
carbamazepine, clofibrate, 
antipsychotic drugs,oxytocin, SSRIs 
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SIADH is diagnosed by exclusion. SIADH is characterised by hypotonic 
hyponatremia in the setting of clinical euvolemia and an inappropriately elevated 
urinary osmolality. Conditions such as hypothyroidism(19) and adrenal 
insufficiency(20) should be ruled out for a diagnosis of SIADH to be made. 
REDISTRIBUTIVE HYPONATREMIA 
 The total body water and sodium levels do not change,but there is relative 
hyponatremia. It is due to the movement of water from inside the cells to 
extracellular space. It occurs due to hyperglycemia and mannitol administration. 
PSEUDOHYPONATREMIA 
 Here also the total body water and sodium is unchanged. But the 
extracellular fluid is diluted with excess of lipids or proteins. It is seen in 
conditions like multiple myeloma and hypertriglyceridemia. 
APPROACH TO HYPONATREMIA 
The specific type of hyponatremia is identified by a systemic approach assessing 
serum osmolarity, volume status and renal sodium excretion in a step by step 
approach. 
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.  
                        Figure 9- Approach to hyponatremia 
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CLINICAL FEATURES OF HYPONATREMIA 
 The severity of symptoms depends upon the severity of hyponatremia and 
the rate of lowering of serum sodium. So acute and severe hyponatremia is 
symptomatic but chronic and mild hyponatremia is well tolerated. Patients with 
extremes of age are more symptomatic. 
Table 4-Clinical features of hyponatremia 
MILD MODERATE SEVERE 
Anorexia 
Headache 
Nausea 
Vomiting 
lethargy 
Personality changes 
Muscle cramps 
Muscular weakness 
Confusion 
Ataxia 
Drowsiness 
Diminished reflexes 
Convulsions 
Coma 
Death 
 
The extracellular sodium is the principal determinant of the extracellular 
osmolarity and the ECF osmolarity is the crucial determinant of many processes 
essential for brain function including excitability, myelination and volume 
regulation. So brain is the most commonly affected organ in hyponatremia. 
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Cerebral adaptation to hyponatremia: 
 The mechanism of brain adaptation to acute and chronic hyponatremia can 
be viewed as a part of the same physiological continuum.  
 Acute hyponatremia is defined as a duration of hyponatremia less than 24-48 
hours. During the first few hours of hyponatremia at the CNS level,the rapid 
decrease in sodium level is followed by an attempt to counterbalance the water 
entry into the cells. A decrease in the extracellular volume and and a quick loss of 
intracellular electrolytes are the first changes seen after acute hyponatremia(21). 
In spite of these changes crebral edema may sometimes occur due to 
a)faster rate of decline in serum sodium than the rate of brain loss of electrolytes. 
b)situations where the magnitude of hyponatremia exceeds the brain‟s capacity to 
adapt. 
 The mechanism of rapid brain adaptation by electrolyte extrusion is 
exhausted by 3 hours and the absence of cerebral edema despite continuation of 
hyponatremia is due to other mechanisms that act in chronic hyponatremia. 
 The brain will also use non-ionic osmotic substances to preserve 
intracellular brain water content. The depletion of these “organic osmolytes” starts 
as early as 4 hours after hyponatremia and reaches its maximum by 4 days. The 
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main organic osmolytes that are depleted in the brain are myoinositol, 
taurine,betaine, glutamate and glycerophosocholine.(22) 
Hyponatremic encephalopathy: 
 The clinical syndrome resulting from the effect of hyponatremia on the brain is 
termed as hyponatremic encephalopathy. 
Risk factors: 
Acuteness and severity of onset of hyponatremia. 
Extremes of age-children and elderly. 
Females are more susceptible. 
Concurrent hypoxia may can impede the mechanism of brain adaptation to 
hyponatremia. 
To summarise, the clinical features of hyponatremia depend on whether its acute or 
chronic(23). 
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                   Figure 10 – Adaptation of brain to hyponatremia 
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Table 5- Clinical features of Acute and Chronic hyponatremia  
Acute hyponatremia 
<48 hours 
Chronic hyponatremia 
>48 hours 
Nausea and vomiting 
Headache 
Disorientation 
Seizures  
Coma  
Respiratory arrest 
Death 
Fatigue 
Confusion 
Somnolence 
Gait deficit 
Attention deficit 
Frequent falls 
 
 
TREATMENT  OF HYPONATREMIA : 
        Treatment of hyponatremia must meet three goals : 
- Plasma sodium concentration must not decrease further. 
- Increase in plasma sodium should be just enough to prevent complications. 
- Avoid iatrogenic neurological injury caused by rapid or excessive 
correction. 
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Different types of hyponatremia can be managed as per the following  guidelines, 
1). Mild asymptomatic hyponatremia – requires no treatment. 
2). Hypovolemic hyponatremia                                                           
       –  These patients require fluid and salt supplementation generally  in the form 
of isotonic saline at a rate appropriate for estimated volume depletion. 
- Fluids like 0.45 % NaCl , Isolyte – M, 5% dextrose must be avoided as it 
aggravates hyponatremia. 
- Diuretics induced hyponatremia is treated with saline with potassium 
supplementation (30 – 40 meq/L).   
3). Hypervolemic hyponatremia 
     -  Restriction of sodium and water intake. 
     -  Loop diuretics causes promotion of water loss in excess of  Sodium. 
- Correction of hypokalemia 
- Treatment of etiology 
- Restriction of dietary water to less than urine output 
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4). Euvolemic hyponatremia 
 In these patients, fluid restriction is the most important treatment. 
5). Acute hyponatremic with neurological symptoms 
            Rapid correction of plasma sodium with hypertonic saline is needed. Initial 
rise of sodium should be 1.5 – 2 meq/L for the first 3 to 4 hours or until severe 
neurological symptoms improve. Once symptoms have improved or seizures stop, 
the correction should not exceed 10 – 12 meq in first 24 hrs. The targeted rate of 
plasma sodium inrease should not be greater than    0.5 meq/L/hr(24). 
                    Increase in plasma sodium by giving 1 litre of different infusate can be 
calculated as 
Change in serum Na
+
  =  
Infusate Na
+
(meq/L) + Infusate K
+
(meq/L) – Plasma Na+(meq/L) 
                          Total body water (L) + 1 
Where total body water is 
  = 0.6 * body weight (kg) in children & non elderly man 
  = 0.5 * body weight (kg) in non elderly woman & elderly man 
= 0.45 * body weight (kg) in elderly woman 
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Table 6:Composition of various I.V fluids 
 
Osmotic demyelination syndrome: 
Rapid correction of hyponatremia (>8-10meq/L in 24 hours or 18meq/L in 48 
hours) is associated with a disruption in the integrity of blood brain barrier, 
allowing the entry of immune mediators that may contribute to demyelination. 
When the hyponatremia is rapidly corrected there is a delay in the reaccumulation 
of organic osmolytes by brain cells as osmolarity increases with correction of 
hyponatremia. The demyelination is more pronounced in pons, but can also occur 
in other structures. Osmotic demyelination syndrome(ODS) can occur as early as 
12 hours but is usually delayed by 2-3 days after the correction of 
hyponatremia.Neurological manifestations of  ODS are as follows(25). 
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Table 7:Manifestations of osmotic demyelination syndrome 
Motor & sensory Neuropsychiatric 
 seizures, coma 
 dysarthria, dysphagia 
 dysmetria, tremors 
 paraplegia 
 locked in syndrome 
 ocular movement disorders 
 cortical blindness 
 dementia 
 altered sensorium 
 depression 
 decreased concentration 
 altered memory 
 catatonia 
 
                     The early diagnosis depends on clinical suspicion & examination in 
conjunction with laboratory analysis and imaging. MRI shows hyperdense lesions 
in T2 – weighted images and hypodense   non – enhancing lesions on T1 – weighted 
images. Pathological findings include a breakdown of blood brain barrier and 
astrocyte loss. 
                    ODS can be prevented by slowly correcting hyponatremia not 
exceeding 10 – 12 meq/L on the first day and less than 18 meq/L over first 48 hrs. 
After rapid correction, relowering of sodium can prevent neurological symptoms 
but should be started within first 24 hrs. 
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LIVER 
The normal adult liver weighs 1.4 to 1.6 kg, constituting approximately 2.5% of 
total body weight. The liver has a variety of functions- synthesis of albumin, 
clotting factors, metabolic functions, detoxification and storage functions.          
 CIRRHOSIS 
Cirrhosis is defined anatomically as a diffuse process with fibrosis and nodule 
formation. The entire architecture of the liver is distorted. There is periportal 
inflammation and bridging fibrosis connecting the portal triads. Nodules develop 
during the process of regeneration.(26) 
               
                      Figure 11: Cirrhotic liver with coarse nodules 
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CAUSES OF CIRRHOSIS: 
The causes include alcohol, infections, autoimmune, metabolic and other causes 
such as cardiac cirrhosis, non alcoholic fatty liver disease,etc. Cryptogenic 
cirrhosis occurs without any identifiable etiology. Drugs like amiodarone, 
methyldopa and methotrexate can cause cirrhosis.  Although the causes are many, 
the pathological changes and end result is the same.  
                
Figure 12- Causes of cirrhosis 
 
48 
 
 
CLINICAL MANIFESTATIONS OF CIRRHOSIS: 
Clinical manifestations depend upon whether the patient has compensated 
disease or decompensated disease. Patients are usually malnourished and 
anemic. Bitot spots and night blindness  may develop due to vitamin A 
deficiency. Anemia may be nutritional, due to hypersplenism, chronic blood 
loss or a combination of all these factors. Platelets are reduced both in 
number and function. Patients usually have mild to moderate jaundice. 
Hypoalbuminemia and coagulopathy occur as a result of impaired synthetic 
functions of liver.  
Patients are prone to develop infections due to decreased immunity. 
Eventually portal hypertension develops and patient develops ascites, 
extensive portosystemic collaterals and splenomegaly. Loss of axillary hair, 
gynaecomastia and testicular atrophy occurs due to hyperestrogenemia. Due 
to long standing abdominal distension, the skin is stretched and shiny. 
Umbilical hernia may develop. Collaterals can be seen around the umbilicus. 
Spider naevi are seen in the front of chest. Long standing cirrhosis is a risk 
factor to develop hepatocellular carcinoma.  
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Figure 13: Clinical manifestations of cirrhosis      
 
Figure 14: Stages of cirrhosis 
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COMPLICATIONS OF CIRRHOSIS(27): 
Portal hypertension 
 Ascites 
 Variceal bleeding 
 Splenomegaly 
 Portal hypertensive gastropathy 
Spontaneous bacterial peritonitis 
Hepatorenal syndrome 
Hepatopulmonary syndrome 
Hepatic encephalopathy 
Coagulopathy 
Hepatocellular carcinoma 
Malnutrition 
Haematological abnormalities 
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PORTAL HYPERTENSION: 
PH refers to an elevated hepatic venous pressure gradient (HVPG) >5mmHg and 
cirrhosis is the most common cause of portal hypertension. In cirrhosis there is 
increased resistance to portal blood flow. The resistance is both mechanical and 
dynamic. Mechanical resistance is due to fibrosis,altered architecture and collagen 
deposition in the space of disse. The cardinal features of portal hypertension are 
ascites, splenomegaly and variceal bleeding. Varices develop at sites of 
portosystemic collaterals.  Varices are commonly present at lower end of 
esophagus, fundus, stomach and also lower part of rectum.  
 
Figure 15: Pathogenic mechanisms in portal hypertension  
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ASCITES: 
 Ascites is caused due to splanchnic vasodilation occurring as a result of 
increase in portal pressure. There is increased hepatic lymph production. 
Decreased synthesis of albumin as a result of liver damage further contributes to 
volume overload and free fluid in the abdomen. The kidneys develop a tendency to 
retain sodium due to drop in effective intravascular volume. All these proposed 
mechanisms involve inappropriate renal sodium and water retention, either 
secondary to intravascular hypovolemia (underfill and peripheral arterial 
vasodilatation theory) or as a primary event (overfill theory). 
Refractory ascites(28) is defined as ascites that cannot be reduced or which 
reaccumulates in spite of continuous maximal medical therapy and diet restriction. 
It is of  2 types. 
o Diuretic resistant: no response to maximum diuretic dose 
o Diuretic intractable: patients do not tolerate diuretics due to 
complications. 
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CLASSIFICATION OF ASCITES               
                
                    Figure 16: Classification of ascites 
SPONTANEOUS BACTERIAL PERITONITIS(SBP): 
 About 8% patients with ascites develop spontaneous bacterial 
peritonitis(29). There is immune dysfunction and decreased opsonins in the ascitic 
fluid that causes translocation of gut organisms resulting in spontaneous infection. 
Infection is usually monomicrobial and gram negative. Ascitic protein <1g/dl 
indictes higher risk.  Ascitic fluid polymorphs >250/mm
3  
is indicative of SBP. 
Mortality is 50% in patients with spontaneous bacterial peritonitis. 69% of patients 
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recur in one year. These patients are at more risk of developing hepatorenal  
syndrome and encephalopathy. 
HEPATORENAL SYNDROME: 
 Hepato-renal syndrome is the development of functional renal failure in 
patients with severe liver disease in the absence of any identifiable renal pathology.  
It occurs secondary to decreased renal perfusion and renal vasoconstriction. About 
20% of cirrhotic patients with ascites and normal renal function develop the 
syndrome after 1 year of follow-up, and 39% at 5 years. Based on the time course 
of development and precipitating factors it is classified into 4 types. 
 
Figure17: Types of hepatorenal syndrome 
The 2 week mortality is as high as 80% in patients with type 1 hepatorenal 
syndrome. 
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. HEPATIC ENCEPHALOPATHY: 
 Hepatic encephalopathy is a reversible neuropsychiatric complication of 
advanced cirrhosis. It occurs due to  increased ammonia in the brain as a result of 
depressed urea cycle. There is an imbalance between inhibitory and excitatory 
neurotransmitters.  Clinical features depends upon the severity of encephalopathy 
and varies from sleep disturbances, disorientation, decreased concentration to 
drowsiness and deep coma. Patients can be categorised according to severity on the 
basis of West havens grading of hepatic encephalopathy. Precipitating factors for 
hepatic encephalopathy are alcohol intake, variceal bleed, constipation, infections, 
electrolyte imbalances and drugs like diuretics and sedatives. 
HYPONATREMIA IN CIRRHOTICS 
 Patients with cirrhosis and ascites have a functional renal failure and 
inability to excrete solute free water. This disorder leads to a disproportionate 
retention of water in relation to sodium which leads to dilutional state and hypo-
osmolarity. 
DEFINITION AND PREVALENCE: 
 Hyponatremia in the general population is defined as serum sodium less than 
135mEq/L(30). However, hyponatremia in cirrhosis is defined as serum sodium 
less than 130mEq/L in the presence of ascites or edema. A significant proportion 
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of cirrhotic patients have serum sodium between 130-135 mEq/L and these patients 
may display pathogenetic and clinical features similar to but less pronounced than 
with patients with serum sodium less than 130mEq/L. In patients with cirrhosis and 
ascites, the 5 year probability of developing hyponatremia is 37% with 25% 
probability of survival at 1 year. It is estimated that 22% of patients with advanced 
cirrhosis have serum sodium levels less than 130mEq/L, however in patients with 
refractory ascites and hepatorenal syndrome, the prevalence may increase upto 
50%(31). If the cutoff  level of 135mEq/L is used then the prevalence goes upto 
49.4%. 
TYPES OF HYPONATREMIA: 
 Table 8: Types of hyponatremia 
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Patients with cirrhosis may develop two types of hyponatremia as explained 
above(32). 
 
PATHOGENESIS OF HYPONATREMIA IN CIRRHOSIS: 
 Patients with cirrrhosis usually have impaired ability to excrete solute free 
water. The degree of impairment varies and patients with moderate impairment can 
be detected by measuring urine volume after water loading test. In cirrhosis there is 
splanchnic vasodilation and extensive peripheral vasodilation. This causes reduced 
effective circulatory volume leading to activation of baroreceptors and non-
osmotic secretion of vasopressin. Other vasopressor systems and antidiuretic 
systems are also activated(33).  In initial stages of disease this compensatory 
neurohemoral mechanism restores the intravascular volume. The compensatory 
mechanisms are transient(34). In advanced disease, there is compensatory 
mechanism failure and persistent activation of vasoconstrictors leading to renal 
sodium retention, edema and hyponatremia. 
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Figure 18: Compensatory mechanisms in cirrhosis 
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MECHANISMS OF WATER RETENTION AND DILUTIONAL 
HYPONATREMIA IN CIRRHOSIS(32): 
1.NON OSMOTIC SECRETION OF AVP(ARGININE-VASOPRESSIN) 
 Increased free water intake in patients with decreased capacity to excrete 
solute free water results in dilutional hyponatremia. Water load test is the standard 
method to estimate renal capacity of free water clearance. About 20 mL/kg of body 
weight of fluid is administered over 45 minutes. 
 In healthy people after fluid loading the serum osmolality falls due to 
dilution in excess of water. This is sensed by the osmoreceptors and there is 
suppression of vasopressin release from hypothalamus. Due to short half life (30 
min) of vasopressin.there is immediate response to changes in osmolality. Due to 
decreased vasopressin, the urine is maximally diluted to upto 40-50 
milliosmoles/kg.  Persons with normal free water clearance excrete more amount 
of diluted urine in 2 hours. This is the normal physiological response. This 
response can be seen even in patients with stable compensated cirrhosis. However 
in patients with advanced decompensated disease, there is impairment of excretion 
of solute free water. The reduction in free water clearance can be correlated with 
severity of the disease, patients with severe disease are unable to produce diluted 
urine. Electrolyte free water clearance can be used to determine the degree of water 
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restriction required to cause negative water balance. It is also used to predict the 
effectiveness and feasibility of using fluid restriction as a mode of treatment.        
                 Bichet et al(35) selected cirrhotic patients with ascites and subjected 
them to water load test. Plasma vasopressin concentrations were measured before 
and after water load. He classified these patients according to the amount of water 
excreted after 5 hours. “Excretors” were those who excreted 80% or more of water 
load and those who were unable to do so called as “non-excretors”.  Non excretors 
had basal vasopressin levels minimally higher than that of secretors. In 
nonexcretors there was no fall in vasopressin in response to change in osmolality 
and vasopressin levels continued to be high independent of hypoosmolality. The 
amount of water excreted was inversely related with vasopressin levels. Higher 
vasopressin levels were found in patients with severe water retention. 
Another similar study(35) classified patients into 2 groups according to 
water excretion after a water challenge test and measured their plasma levels of 
various vasomediators. Group of patients unable to excrete solute free water had 
higher levels of vasopressin confirming its role in causing water retention. 
Moreover these patients had increased plasma renin, aldosterone and nor 
epinephrine levels compared to the other group. This shows the role played by 
pathological hyperstimulation of sympathetic system and renin angiotensin system 
in response to decreased circulatory volume. These two studies  proposed a 
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nonosmotic stimulation for VP release in cirrhotic patients with impaired water 
excretion. 
           
             Figure 19: Role of vasopresssin  
 Studies using vasopressin antagonists (vaptans)for the treatment 
of hypervolemic hyponatremia in cirrhosis showed that vaptans caused an increase 
in serum sodium in about 60-70% of patients(36). This strongly emphasises that 
hypersecretion of vasopressin plays a major role in the pathology of hyponatremia. 
But in a small percentage of patients vaptans could not increase the sodium levels 
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suggesting that other mechanisms are also involved in water retention other than 
vasopressin. 
2.DECREASED METABOLISM OF VASOPRESSIN: 
 Vasopressin is metabolised in the liver and kidneys(37). In 
cirrhosis, the functions of liver are deranged. The normal half life of VP is only 30 
minutes. Due to liver dysfunction the half life of VP may be prolonged causing 
pathological reabsorption of excess water. This prolonged action in addition to 
increased secretion can act synergistically to cause antidiuresis. 
3.DECREASED DISTAL SODIUM DELIVERY: 
  Normally 60-75% of sodium is reabsorbed in proximal tubules, 
but in cirrhosis there is excessive reabsorption due to decreased renal perfusion. 
The amount of fluid delivered to the distal segment is reduced progressively due to 
decline in glomerular filtration. The upper limits of urine output is determined by 
the amount of fluid reaching the distal tubules. Due to renin angiotensin activation, 
excess aldosterone causes increased sodium reabsorption. In physiological states, 
along with sodium, fluid is also reabsorbed and there is increased fluid delivery to 
distal tubule resulting in pressure natriuresis. This is called aldosterone escape. 
This is impaired in cirrhosis due to decreased filtrate reaching the distal portion of 
the nephron. This is also a contributing factor for reduced response to atrial 
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natriuretic peptide in patients with cirrhosis. Researchers calculated distal fluid 
delivery by using lithium clearances in cirrhosis and found a significant 
reduction(38). 
4.REDUCTION IN RENAL PROSTAGLANDINS(39): 
 Prostaglandins are secreted in the kidney by glomerular and vascular 
endothelium. These have local actions but no systemic effect. These are 
endogenously produced vasodilators that try to maintain renal blood flow and 
glomerular filtration. In cirrhosis patients, the renal hemodynamics is altered more 
towards vasoconstriction. Prostaglandins act as a defence against vasoconstrictive 
effects of angiotensin II, vasopressin and norepinephrine that are found in high 
levels in cirrhosis. There are studies which propose that prostaglandins inhibit VP-
stimulated water reabsorption. Effects of non-steroidal anti inflammatory 
drugs(NSAIDs) in cirrhosis causing deterioration of renal function is an indirect 
evidence of the role played by prostaglandins(40). It is probably due to loss of 
protective role of prostaglandins due to inhibition of production by NSAIDs. In 
cirrhosis patients there is impaired production of renal prostaglandins. 
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PROGNOSIS OF CIRRHOTIC PATIENTS: 
 Cirrhosis is a chronic disease and hence a standard prognostic tool is 
required in order to understand the severity and staging of disease and predict 
mortality and morbidity based on previous data. Moreover prognostic 
categorisation of patients is required to make treatment decisions, estimate risk 
involved in interventions, surgeries and shunt procedures. They are also used to 
determine the threshold for listing patients for liver transplantation, predict survival 
following transplant and to select patients waiting for transplant. Current scores 
available are: 
1.CHILD PUGH TURCOTTE SCORE(CPS) 
2.MODEL FOR END STAGE LIVER DISEASE SCORE(MELD) 
CHILD PUGH TURCOTTE SCORE: 
 The scoring system was first proposed by Dr C.G.Child and Dr J.G.Turcotte 
of University of Michigan in 1964 and originally used to predict mortality during 
surgery(41). It used 5 variables ascites, bilirubin, albumin, hepatic encephalopathy 
and malnutrition. The selection was based on observations made by clinical 
experience. In 1972 it was modified by Pugh et al, nutritional status was replaced 
by elevation in prothrombin time or INR. Each variable was assigned scores1-3 
and a total for 15 is made. 
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 Figure 20:MODIFIED CHILD PUGH SCORE 
Based on total points, Child A = 5–6 points, Child B = 7–9 points,  Child C = 10–
15 points.  
INTERPRETATION 
Based on the category the survival is predicted as follows(42). 
 
           Figure 21: Interpretation of child pugh score 
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MELD SCORE: 
 It was originally developed by Dr Patrick Kamath at mayo 
clinic to predict the likelihood of survival in cirrhotic patients with refractory 
ascites undergoing transjugular intrahepatic portosystemic shunt (TIPSS)(43). 
Researchers discovered the four objective variables capable of independently 
predicting survival in these patients in a multivariate Cox model. These were 
bilirubin, creatinine, INR and cause of cirrhosis (alcohol and cholestatic versus 
other causes). It is calculated using the formula 
MELD= 3.78 × log[serum bilirubin(mg/dl)] + 11.2 × log[INR] + 9.57×log[serum 
creatinine(mg/dl)] + 6.43×[etiology] 
Etiology:0-cholestatic/alcohol,1-others. 
Each variable was log transformed and had a regression coefficient attached 
relative to its individual contribution to the model. Then years later, it was also 
used to allocate patients for liver transplantation based on severity.(44) Later 
studies found out that the etiology turned out to be relatively unimportant  and the 
score was calculated as 
MELD= 3.78 × log[serum bilirubin(mg/dl)] + 11.2 × log[INR] + 9.57×log[serum 
creatinine(mg/dl)] + 6.43. 
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This score was also extensively studied in hospitalized cirrhotic patients, 
ambulatory patients without cholestasis, patients with Primary Biliary Cirrhosis 
and a large unselected patient cohort from the 1980s. 
Interpretation: 
The 3 month mortality based on MELD score in hospitalised patients is 
 Table 9: Interpretation of MELD. 
Score Mortality in% 
40 or more 71.3 
30-39 52.6 
20-29 19.6 
10-19 6.0 
<9 1.9 
 
Caveats within score: 
 The maximum score given for MELD is 40. All values higher than 40 are 
given a score of 40. 
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 Maximum value for creatinine was 4 and if the patient has underwent 
dialysis twice within the last week, the value for serum creatinine used 
should be 4.0. 
 Any value less than one is given a value of one (i.e. if bilirubin is 0.8, a 
value of 1.0 is used). 
PROGNOSTIC VALUE OF SODIUM(49): 
 Hyponatremia in cirrhosis is a chronic process and this allows 
the brain to adapt to the hypo-osmolality of the extracellular fluid. Patients with 
cirrhosis and hyponatremia are less likely to have severe neurologic symptoms due 
to the fact that hyponatremia develops very slowly(32). However, hyponatremia 
may pose a additional insult to cerebral edema and astrocyte swelling, in addition 
to the astrocyte dysfunction caused by increased intracellular glutamine 
concentration from ammonia metabolism, thereby precipitating hepatic 
encephalopathy.  
The quality of life is poor in patients with cirrhosis and hyponatremia due to the 
requirement for strict fluid restriction. Hyponatremia has been found to be an 
independent predictive factor of the impaired health related quality of life(45) as 
well as hepatic encephalopathy(46). Many studies suggest that the extent of 
hyponatremia and severity of ascites can be used to determine disease severity and 
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prognosis in cirrhosis. The degree of hyponatremia is proportional to the 
circulatory dysfunction and secondary sympathetic system activation. In one study, 
the serum sodium level before the onset of spontaneous bacterial peritonitis (SBP) 
was an independent predictor of renal failure triggered by SBP. It has also been 
suggested that serum sodium is more sensitive test than serum creatinine to detect 
circulatory dysfunction resulting in renal failure or death. Sodium levels rose even 
before creatinine level raised. Although patients with hyponatremia are at a very 
high risk for developing hepatorenal syndrome, low serum sodium in hepatorenal 
syndrome is not only due to high ADH levels but also due to decreased GFR and 
proximal sodium reabsorption.  
 Patients with hyponatremia were found to have a higher risk of 
early death before transplantation independent of the severity of cirrhosis as 
assessed by the MELD scores. Sodium and MELD score proved to be independent 
prognostic factors. Hence, some investigators have advocated a prioritised liver 
transplantation under a „sickest first‟ model based on sodium values in cirrhotic 
patients with MELD scores below 21, persistent ascites and hyponatremia. These 
studies formed the basis of a suggestion that serum sodium could be incorporated 
into the MELD score(47), and this may provide a more accurate survival prediction 
than MELD alone.(48) 
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MATERIALS AND METHODS 
Source of the study: 
The study was conducted on 100 patients admitted in Government Mohan 
Kumaramangalam Medical College Hospital diagnosed to have cirrhosis during the 
study period August 2014- August 2015. 
Method of collection of data: 
 The data of the patients was collected in a well designed proforma. Informed 
consent was obtained from all the patients. Patients diagnosed to have cirrhosis 
based on clinical examination and investigations were selected. A detailed history 
was taken and all essential investigations done. Serum sodium was measured in all 
the patients. Based on investigation results, Child-Pugh score and MELD score 
was calculated for all patients to assess severity of cirrhosis. Complications present 
in all the patients was documented. 
Inclusion criteria: 
 Patients with cirrhosis 
 Both sexes included 
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Exclusion criteria: 
 Patients with cardiac disease 
 Patients with chronic kidney disease 
 Patients on diuretics 
Statistical analysis: 
Tabulation and statistical analysis were performed using Microsoft excel and SPSS 
v.17.0 software. Numerical data were summarised by measures of central 
tendency:mean and standard deviation. Qualitative data was analysed with 
descriptive statistics & a two way univariate analysis was used for comparison of 
study variables. If p value < 0.05 at 95% confidence interval it is taken as 
statistically significant. 
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OBSERVATIONS AND RESULTS 
The study included 100 patients with cirrhosis out of which 93 patients were males 
and 7 patients were females. The mean age of the patients was 48.27±10.85 years. 
The basic demographic details of the patients is given in the table below. 
Table 10:Basic demographic details of the patients 
S.NO PARAMETER N=100 
1 Age(years)(Mean±SD) 48.27±10.85 
2 Sex: (number)(%) 
      Males 
      females 
 
93 
7 
3 Cause of cirrhosis(no)(%) 
      Alcohol 
      Hepatitis B 
      Hepatitis C 
 
96 
2 
2 
4 MELD score (Mean±SD) 22.53±8.16 
5 Serum Na
+
 (Meq/L)(Mean±SD) 
a) ≤130Meq/L 
b)131-135 Meq/L 
c) ≥136 Meq/L 
(Number%) 
131.38±9.38 
31(31%) 
21(21%) 
48(48%) 
 
About 96% of the cirrhosis patients were due to alcohol, 2% of cirrhosis was 
due to hepatitis B infection, 2% were due to hepatitis C infection. Alcohol was the 
most common cause contributing to about 96% of cirrhosis. The MELD score of 
the patients ranged from 9-46, the mean MELD score was found to be 22.53±8.16.  
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The serum sodium level  of the patients ranged from 108 to 145 Meq/L. The mean 
sodium score of the patients was 131.38±9.38. Based on the diagnostic criteria of 
hyponatremia in cirrhosis 31(31%) patients had serum sodium ≤ 130 Meq/L. 
21(21%) patients had mild hyponatremia with serum sodium between 131-135 
Meq/L. The remaining 48 patients had serum sodium ≥136 Meq/L. 
        
                  
Figure 22:Bar diagram showing sex distribution of cirrhotic patients 
The male :female sex ratio is around 13.2:1 in our study. Male preponderance for 
cirrhosis is due to the increased alcohol intake in males compared to females. 
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Figure 23:Pie chart showing etiological causes of cirrhosis 
96% of the cases were due to alcohol and 2 cases were due to Hepatitis B and 
Hepatitis C infection each. 
                    
Figure 24:Bar diagram showing distribution of patients according to 
serum sodium concentration in Meq/L. 
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Among the 100 patients , 31 patients had serum sodium≤ 130Meq/L. 21 patients 
had mild hyponatremia with serum sodium concentration between 131-135 Meq/L. 
Remaining 48 patients had normal serum sodium concentration >135Meq/L. 
 
Figure 25: Pie chart showing distribution of serum sodium 
 
 
 
 
31% 
21% 
48% 
PERCENTAGE OF PATIENTS 
≤130Meq/L 
131-135Meq/L
>135Meq/L
76 
 
Table 11:CHARACTERISTICS OF PATIENTS BASED ON SERUM 
SODIUM 
S.N
O 
PARAMETER Na
+≤130Meq/L 
(N=31) 
Na
+ 
131-
135Meq/L 
(N=21) 
Na
+≥136Meq/L 
(N=48) 
1. Age(mean ± 
SD)(years) 
45.47±10.28 45.75±11.93 44.09 
±9.64  
2. Sex: 
M 
F 
 
27(87%) 
4(13%) 
 
20(95%) 
1(5%) 
 
46(96%) 
2(4%) 
3. Cause of 
cirrhosis 
Alcohol 
Hepatitis B 
Hepatitis C 
 
 
30 
1 
- 
 
 
20 
1 
- 
 
 
46 
0 
2 
4. MELD 
* 
(MEAN±SD) 
27.45±9.24 24.76±6.86 18.38±5.46 
5. Child-Pugh 
@ 
score 
(MEAN±SD) 
 
11.29±1.49 
 
10.76±1.48 
 
9.63±1.65 
 Class A
# 
Class B 
Class C 
0 
3 
28 
0 
3 
18 
4 
13 
31 
*-p value<0.001, @ p value<0.001,# p value-0.049 
The patients were divided into three categories based on serum sodium to compare 
patients belonging to each category. The mean age of the patients with serum 
sodium≤130Meq/L,131-135 Meq/L and ≥136Meq/L were 45.47±10.28, 
45.75±11.93 and 44.09±9.64 respectively. The age of the patients was comparable 
in all the 3 categories and did not show any statistical significance.  
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Frequency of gender among these 3 groups was studied and did not show any 
significant correlation with serum sodium with a p value of 0.299. 
 
Figure 26: Bar diagram showing gender distribution according to 
serum sodium. 
 The etiology of cirrhosis was studied in the 3 groups and did not show any 
correlation with serum sodium . 
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Figure 27: Bar diagram showing cause of cirrhosis according to serum 
sodium 
Thus age, sex and etiology did not show any correlation with serum sodium and 
degree of hyponatremia. 
The mean MELD score in patients with serum sodium ≤130Meq/L, 131-135 
Meq/L and ≥136Meq/L was 27.45±9.24, 24.76±6.86 and 18.38±5.46 respectively. 
The association was found to have high statistical significance and p value <0.001. 
Patients with severe hyponatremia had higher mean MELD score compared to 
patients with normal sodium. 
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Table 12: Mean MELD score in various categories 
SERUM SODIUM IN MEQ/L MEAN MELD SCORE 
≤130 27.45±9.24 
131-135 24.76±6.86 
≥136 18.38±5.46 
P VALUE- <0.001 
                      
Figure 28:Bardiagram showing mean MELDscore according to serum sodium 
Patients in each category were assessed for disease severity using Child 
Pugh score with severe disease having higher scores. The mean Child Pugh score 
in patients with serum sodium ≤130Meq/L, 131-135 Meq/L and ≥136Meq/L was 
11.29±1.49, 10.76±1.48 and 9.67±.65 respectively. Patients with lower sodium 
levels had more severe disease as indicated by higher CPS scores. 
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90.32 % with serum sodium ≤130meq/L belonged to class C as compared to 
85.71% in patients with sodium between 131-135 and 64.58% in patients with 
sodium >135 meq/L. The analysis showed significant statistical correlation with p 
value of 0.049. 8.33% of patients with sodium >135Meq/L belonged to child-pugh 
class A whereas no patient with serum sodium≤ 130 Meq/L belonged to child pugh 
class A. Only 9.68% of patients with sodium≤ 130Meq/L belonged to classB 
whereas 14.29% of the second category and 27.08% with serum sodium 
>135Meq/L belonged to class B. 
      
Figure 29: Bar diagram showing subclassification of patients into child pugh 
severity class. 
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 Table 13: FREQUENCY OF COMPLICATIONS IN STUDY PATIENTS 
S.NO COMPLICATION FREQUENCY(%) 
1 Ascites 95 
2 Portal hypertension(PHT) 98 
3 Hepatic encephalopathy(HE) 33 
4 Variceal bleeding 28 
5 Coagulopathy 17 
6 Hepatorenal syndrome(HRS) 9 
 
 
Among the 100 patients studied 95(95%) had ascites, 98(98%) had portal 
hypertension, 33(33%) patients developed hepatic encephalopathy. Variceal 
bleeding was present in 28(28%) patients and coagulopathy was present in 
17(17%) persons. 9 patients(9%) developed hepatorenal syndrome. 
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Figure 30: 
Bar diagram showing frequency of various complications in 100 patients 
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Table 14:  FREQUENCY OF COMPLICATIONS ACCORDING TO 
SERUM SODIUM 
 
 
There was a no significant difference in between these 3 groups of sodium levels in 
the frequency of ascites and portal hypertension. The p values were not significant. 
There was no significant correlation between sodium level and variceal bleeding 
(p value 0.06). 
S.
N
O 
COMPLICATIONS Na
+≤130 
meq/L 
(n=31)
 
Na
+ 
131-135 
Meq/L 
(n=21) 
Na
+≥136 
Meq/L 
(n=48) 
Chi 
square 
P 
value 
1 Ascites 31 
(100%) 
21 
(100%) 
43 
(89.58%) 
5.7 0.058 
2 Portal hypertension 31 
(100%) 
21 
(100%) 
46 
(95.83%) 
2.21 0.331 
3 Hepatic 
encephalopathy(HE) 
20 
(64.52%) 
10 
(47.62%) 
3 
(6.25%) 
31.49 <0.00
1 
4 Variceal bleeding 11 
(35.48%) 
10 
(47.62%) 
7 
(14.58%) 
9.16 0.06 
5 Coagulopathy 10 
(32.26%) 
2 
(9.52%) 
5 
(10.42%) 
7.42 0.024 
6 Hepatorenal 
syndrome(HRS) 
7 
(22.58%) 
2 
(9.52%) 
0 11.14 0.003 
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There was significant difference between 3 groups in the occurrence of hepatic 
encephalopathy, coagulopathy and hepatorenal syndrome. The p values were 
0.001, 0.024 and 0.003 repectively. 
 
Figure 31: Bar diagram showing comparison of complications between 
various sodium levels 
 
Patients with sodium less than 130 meq/L had more incidence of complications 
when compared to patients with higher sodium concentration. 
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Table 15: COMPARISON OF COMPLICATIONS ACCORDING TO 
SERUM SODIUM CONCENTRATION 
 
COMPLICATIONS Sodium 
≤130meq/L 
Sodium 
131-135meq/L 
 
Odds ratio 
(95%CI) 
P value 
Odds ratio 
(95%CI) 
P value 
ASCITES 14.8 0.0647 12.8 0.128 
PHT 38.5 0.2553 33.5 0.350 
HE 0.411 0.0001 0.232 0.001 
Coagulopathy 0.234 0.0153 0.113 0.912 
HRS 0.097 0.0004 0.03 0.030 
Variceal  Bleeding 0.295 0.0307 0.327 0.003 
 
CI-confidence interval 
Patients with serum sodium ≤ 130meq/L had increased risk of complications 
when compared to patients with serum sodium >135meq/L. There was increased 
risk of hepatic encephalopathy(p value-0.0001), coagulopathy(p value-0.0153), 
hepatorenal syndrome(p value-0.0004) and variceal bleeding(p value-0.037).  
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Ascites and portal hypertension were not associated with increased risk in patients 
with serum sodium≤ 130meq/L(p values were not significant). 
Patients with serum sodium between 131-135meq/L when compared to 
patients with serum sodium>135 meq/L had increased risk of hepatic 
encephalopathy   (p value 0.001), hepatorenal syndrome(p value 0.030) and 
variceal bleeding     (p value 0.003).  These patients did not have increased risk of 
ascites(p value-0.128), portal hypertension(p value-0.350) and coagulopathy(p 
value-0.912). 
 
Table 16: OUTCOME OF PATIENTS UNDER STUDY 
Total no of patients No of deaths Patients on treatment 
100 9 91 
 
Out of the 100 patients studied, 9 patients died. 
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               Figure 32: Pie chart showing mortality rate of patients studied 
Table 17: MORTALITY ACCORDING TO SERUM SODIUM 
P value<0.05-statistically significant 
7(22.6%) out of 31 patients with serum sodium died and 2(9.5%) out of 21 
patients with serum sodium between 131-135meq/L died. No patient in the group 
with serum sodium> 135meq/L died. There was significant statistical correlation of 
mortality with serum sodium in these 3 groups.  
91 
9 
OUTCOME 
patients on treatment death
SERUM 
SODIUM 
≤130Meq/L 131-135 
Meq/L 
>135 Meq/L P VALUE 
MORTALITY 7(22.6%) 2(9.5%) 0 0.003 
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Figure 33: Bar diagram showing percentage of mortality according to serum 
sodium. 
Patients with severe hyponatremia had increased mortality(22.6%) when compared 
to patients with mild hyponatremia(9.5%). There was no mortality in patients with 
sodium >135meq/L.  
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DISCUSSION 
Hyponatremia is the most prevalent electrolyte imbalance in hospitalised 
patients. Dilutional hyponatremia(50) is common in patients with cirrhosis, it 
develops as a result of compensatory mechanisms that act to increase the effective 
circulatory volume. Therefore more severe form of the disease is associated with 
robust activation of compensatory mechanisms and the extent of hyponatremia can 
give as an idea about the severity of the underlying pathology. There has been 
recent interest in using sodium as a variable to prognosticate cirrhotic patients. 
Our study was done to study the prevalence of hyponatremia and its association 
with various complications of the disease.  
In our study the prevalence of hyponatremia as per definition ≤ 130 Meq/L was 
found to be 31%. The prevalence was 52% for serum sodium cut off value of 
135Meq/L. 48 % patients had normal sodium levels. Several studies showed 
similar incidence of hyponatremia in patients with cirrhosis. 
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Table 18: STUDIES COMPARING PREVALENCE OF HYPONATREMIA 
Studies 
Prevalence of hyponatremia% 
≤130 131-135 ≥136 
Present study (n=100) 31%(31/100) 21%(21/100) 48%(48/100) 
Angeli P et al(51) 
(n=997) 
21.6% 
(211/997) 
27.8% (275/997) 50.6% 
(497/997) 
Jong H Kim et al(52) 
(n=188) 
27.1% (51/188) 20.8% (39/188) 52.1% (98/188) 
Shaikh S (53) (n=217) 
26.7% (58/217) 24.9% (54/217) 48.4% 
(105/217) 
Borroni G et al (54) 
(n=156) 
29.8% (57/156) 
 
  
Similar study was conducted by Angeli et al in 997 consecutive patients from 28 
centers in  4 continents Europe, Asia, North and South America . The study was 
conducted for a period of 28 days. The prevalence of hyponatremia was found to 
be 21.6% and 27.8% in the categories of sodium ≤130 and 131-135Meq/L. The 
patients with lower sodium levels had more complications and more difficult to 
treat ascites, poorly responding to medical therapy. 
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Another study by Sheikh et al was a case control study consisting of 217 patients. 
The incidence of hyponatremia was 58/217(26.7%). 54(24.9%) patients had serum 
sodium between 131-135Meq/L. The remaining 48. 4% patients had normal serum 
sodium. 
Yet another study conducted by Jong Hoon Kim et al conducted on 188 patients 
showed 27.1%, 20.8% and 52.1% patients with serum sodium≤130, 131-135 and 
≥136 Meq/L respectively. 
Table 19:COMPARISON OF PREVALENCE OF HEPATIC 
ENCEPHALOPATHY 
Studies Frequency of hepatic encephalopathy 
≤130 131-135 ≥136 
Present 
study(n=100) 64.52%(20/31) 47.62%(10/21) 6.25%(3/48) 
Angeli P et al 
(n=997) 38% 24% 15% 
Kim JH et al 
(n=188) 23% 14% 24% 
Shaikh S et al 
(n=217) 25.8%   
 
In our study the frequency of hepatic encephalopathy was 64.52% in pateints with 
hyponatremia and 47.62% and 6.25% in patients of other two categories. The 
frequency of encephalopathy in patients with hyponatremia in other studies varied 
from 23% to 38% respectively. 
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Qureshi(55) et al studied patients admitted to shifa hospital, Islamabad. He selected 
202 patients with cirrhosis and hepatic encephalopathy and measured their sodium 
values. Patients were graded according to severity of encephalopathy. Patients with 
lower sodium had higher incidence of encephalopathy and higher grade of 
encephalopathy according to West Havens grading. 
Guevera et al(56) did a prospective study on 61 patients for 1 year while 
monitoring their sodium levels every week. He looked for the development of 
encephalopathy and correlated with serum sodium values. He concluded that 
sodium could be used to predict onset of encephalopathy. 
Hyponatremia acts as a further insult to the already damaged brain in cirrhosis due 
to various factors such as hyperammonemia, altered neurotransmitters. Both 
hyponatremia and hyperammonemia cause shift of extracellular water into 
astrocytes. This causes astrocyte swelling and reduction in osmolytes. This leads to 
brain dysfunction. Thus hyponatremia acts as an independent risk factor for hepatic 
encephalopathy. Studies by Guevera et al showed that patients with decreased 
serum sodium had decreased intracellular osmolytes in astrocytes, especially 
myoinositol. Patients who went in for hepatic encephalopathy had decreased 
myoinositol levels. This suggests us a new treatment strategy to treat hyponatremia 
in order to prevent hepatic encephalopathy.  
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Table 20: COMPARISON OF PREVALENCE OF HEPATORENAL 
SYNDROME 
Studies 
 
Frequency of hepatorenal syndrome 
 
≤130 131-135 ≥136 
Present 
study(n=100) 
22.58%(7/31) 9.52%(2/21) 0 
Angeli P et al 
(n=997) 
17% 10% 6% 
Kim JH et al 
(n=188) 
3.9% 2.5% 3% 
 
The incidence of hepatorenal syndrome was 22.58% in pateints with hyponatremia 
and 9.52% in patients with intermediate sodium levels and none of the patients 
with normal sodium had hepatorenal syndrome. 
The prevalence of hepatorenal syndrome in patients with hyponatremia in other 
studies ranged from 3.9% to 17%. Patients with severe hyponatremia usually have 
more decreased effective circulatory volume and decreased renal perfusion leading 
to more number of cases of hepatorenal syndrome. Hepatorenal syndrome usually 
sets in only after the exhaustion of compensatory mechanisms and persistent renal 
retention of sodium. So it is logical to think that serum sodium starts falling earlier 
than when actual hepatorenal syndrome develops. Serum sodium can hence be 
used to reasonable extent to assess the risk of development of renal failure. 
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When patients were classified according to severity using child pugh score, 
among 31 patients with hyponatremia 90.3% belonged to child Pugh class C 
whereas among patients with sodium131-135meq/L 85.7% belonged to class C. 
among patients with normal sodium only 64.6% belonged to class C. This shows 
that in liver cirrhosis, the more severe the hyponatremia the more severe is the 
underlying disease.  
Table 21: MORTALITY RATE ACCORDING TO SERUM SODIUM 
Serum sodium(meq/L) No of deaths 
≤130 7(22.6%) 
131-135 2(9.5%) 
≥136 0 
 
When comparing the mortality rate among 3 categories, 7 out of 31 with 
hyponatremia died, 2 out of 21 with sodium 131-135meq/L died but no deaths 
occurred in patients with normal sodium. In another study on patients with 
cirrhosis the mortality rate among patients with sodium ≤ 130 meq/L was found be 
27%. Similar mortality rate was found in our study also. Patients in that study with 
sodium <125 meq/L showed even higher mortality rate of 48%. Thus serum 
sodium correlates with morbidity and mortality and can be used as a prognostic 
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factor in patients with cirrhosis. Hence our study suggests the importance of 
treating hyponatremia in cirrhosis. Improvement of hyponatremia reduces the need 
for very strict fluid restriction in patients. It also reduces the risk of complications.  
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CONCLUSION 
Hyponatremia is very common in patients with cirrhosis, mostly as a result of 
dilutional hyponatremia. The severity of decrease in sodium levels is associated 
with increased risk of complications such as hepatic encephalopathy, hepatorenal 
syndrome and coagulopathy. Patients with severe hyponatremia are also associated 
with significantly higher rates of morbidity and mortality. 
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SUMMARY 
 The present study was conducted on 100 patients diagnosed with cirrhosis in 
Government Mohan Kumaramangalam Medical College Hospital in salem 
from August 2014-August 2015. 
 All cases were evaluated with detailed history and relevant investigations. 
 Out of 100 patients 93 were males and 7 were females 
 The prevalence of hyponatremia was found to be 31% and it increased to 
about 52% if a cut off value of 135meq/L was taken. 
 Severity of hyponatremia was associated with increased severity of 
complications. 
 Severe hyponatremia had increased correlation with hepatic encephalopathy, 
hepatorenal syndrome and coagulopathy. 
 Ascites and portal hypertension was not significantly associated with serum 
sodium levels 
 Mortality rate in this study was 9% 
 Severe hyponatremia was associated with increased mortality 
 Hence hyponatremia can be used to predict prognosis of a patient with 
cirrhosis. 
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PROFORMA 
   
Name:      Age/sex:   
Address: 
 
 
O.PNo:       I.P No:                                                                                   
D.O.A:      D.O.D: 
 
 CHIEF COMPLAINTS:    YES   NO 
Jaundice 
Abdominal distention 
Leg swelling 
Fever 
Bleeding 
Abdominal pain 
Altered sesorium 
Others 
 
PAST HISTORY: 
 
PERSONAL HISTORY: 
 
FAMILY HISTORY: 
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PERSONAL HISTORY: 
Alcohol 
Smoking 
 
GENERAL PHYSICAL EXAMINATION: 
Nourishment      anemia 
Jaundice     cyanosis 
Clubbing     pedal edema 
lymphadenopathy 
Vitals: PR                : 
            BP                :  
            RR                :     
            Temperature : 
            Weight          : (      ) kg 
Signs of liver cell failure 
 
SYSTEMIC EXAMINATION:   
1. Abdomen:   ascites 
 Liver    spleen 
 Bowel sounds 
 
2. Respiratory system: 
 
3. Cardiovascular System:S1 S2    murmurs 
107 
 
   
 
4. Central Nervous System:sensorium 
   asterixis 
 
COMPLICATIONS: 
 Ascites 
 Hepatic encephalopathy 
 Hepatorenal syndrome 
 Coagulopathy 
 Bleeding varices 
 others 
      
INVESTIGATIONS: 
Complete blood count 
Renal function tests 
Electrolytes including serum sodium 
Urine complete 
Liver function tests 
Prothrombin time,INR 
USG Abdomen 
Ascitic fluid analysis 
Upper GI Endoscopy 
  
MASTER CHART 
S.NO NAME AGE/SEX ASCITES PHT HE COAG HRS UREA Cr VB Na TB/DB TP/ALB AST/ALT/ALP PT/INR MELD CPS CAUSE OUTCOME 
1 Sengottuvel 40/M P P P P P 160 4.8 P 118 16/ 8.2 6.3/ 3 80/ 60/ 140 48/ 3.2 43 13 ALC D 
2 Shanmugam 43/M P P A A A 32 1.3 A 136 5/ 3.8 5.3/ 2.8 74/ 68/ 158 15/0.9 15 9 ALC OT 
3 Raman  38/M P P A A A 33 0.9 A 139 6.3/ 2.8 6.2/ 3.6 46/ 29/ 98 14/1 13 8 ALC OT 
4 Kangamuthu 55/M P P P A A 40 0.7 A 132 10.2/ 5.6 7.4/ 2.8 36/ 68/ 158 23/1.2 17 10 ALC OT 
5 Venkatappan 30/M P P P A A 26 0.8 A 120 8.9/ 4.3 8.6/ 3.9 69/ 82/ 177 24/1.8 21 10 ALC OT 
6 Rajendran 48/M P P A A A 22 1.1 P 136 4.2/ 2.1 7.4/ 2.9 45/ 77/ 154 22/1.6 18 9 ALC OT 
7 Mani 48/M P P A P P 49 3.2 A 122 18.4/ 11.6 5.2/ 2.0 90/ 70/ 126 74/4.0 44 13 ALC OT 
8 Suresh kumar 48/M P P A A A 18 1.2 A 131 8.4/ 6.3 8.1/ 3.3 77/ 69/ 101 29/1.9 23 10 ALC OT 
9 Chella durai 36/M P P P A A 17 0.5 A 110 11/ 5.5 9.5/ 2.6 59/ 49/ 188 27/1.3 18 11 ALC D 
10 
Mohana 
sundaram 33/M P P A P A 22 
0.8 
A 140 2.5/ 1.2 7.0/ 4.4 48/ 66/ 159 32/2.9 22 9 ALC OT 
11 Jayaraman 48/M P P A A A 16 0.7 A 118 6.8/ 2.1 8.0/ 2.9 50/ 61/ 97 16/1.1 15 9 ALC OT 
12 Murugesh 53/M P P A A A 25 0.9 A 134 7.0/ 3.2 5.9/ 2.9 46/ 33/ 131 19/1.5 18 9 ALC OT 
13 Chellapan 60/M P P A A A 28 0.4 A 138 2.3/ 0.9 6.6/ 2.8 20/ 55/ 155 17/1.7 16 8 ALC OT 
14 Backiyalakshmi 55/F P P P A A 35 0.8 A 120 7.6/ 1.6 8.4/ 3.7 44/ 66/ 147 19/0.9 14 9 ALC OT 
15 Kaliyappan 36/M P P A A A 33 0.8 A 136 6.9/ 3.1 7.3/ 2.7 55/ 33/ 100 11/0.8 14 10 HEP C OT 
16 Paramasivam 35/M A P A A A 28 0.9 A 139 1.9/ 1.2 5.3/ 3.1 77/ 29/ 92 18/1.2 11 6 ALC OT 
17 Ayyanar 38/M P P A A A 26 1 A 120 8.8/ 1.8 8.0/ 4.0 66/ 39/ 88 22/1.8 21 9 ALC OT 
18 Veeran 58/M P P A A A 30 1.1 A 138 9.3/ 5.8 8.0/ 2.9 104/ 98/ 199 32/2.6 26 12 ALC OT 
19 Kuppusamy 75/M P P P P P 80 3.8 P 133 10/ 4.2 8.2/ 1.5 29/ 39/ 166 78/5 46 14 HEP B D 
20 Palaniyappan 69/M P P A A A 18 0.8 A 136 3.2/ 2.3 7.2/ 3.0 44/ 66/ 161 27/1.5 15 9 ALC OT 
21 Rajamani 48/F P P A A A 22 0.4 A 130 8.8 /2.7 7.3 /3.5 57/39/105 31/ 2.1 23 10 ALC OT 
22 Ramesh 46/M P P P A A 20 0.3 A 116 9.7 /2.8 6.6/ 1.4 38/ 44/ 104 33/2.2 24 12 ALC OT 
23 Vadivel 40/M P P P A P 86 3.8 P 110 12/ 5.7 5.9/ 2.6 44/ 55/ 178 36/ 2.4 38 13 ALC OT 
24 Perumal 49/M A A P A A 21 0.6 A 138 2.4 /0.9 6.2/3.6 58/ 66/ 111 13/ 0..9 10 6 ALC OT 
25 Kandan 60/M P P A A A 30 0.7 A 138 3.6 / 2.8 7.5/ 2.8 44/ 61/ 89 14/ 1 11 9 ALC OT 
S.NO NAME AGE/SEX ASCITES PHT HE COAG HRS UREA Cr VB Na TB/DB TP/ALB AST/ALT/ALP PT/INR MELD CPS CAUSE OUTCOME 
26 Udhaya kumar 25/M P P A A A 35 1.1 A 144 5.2/ 2.2 8.3/ 4.2 76/ 89/ 121 18/ 1.2 16 8 ALC OT 
27 Hazeeb 37/M P P A A A 36 0.9 P 134 9.5 /4.6 8.3/ 2.2 88/ 29/ 131 33/ 2.1 23 11 ALC OT 
28 Kaliyan 62/M P P A A A 31 1.2 A 138 4/2.2 8.8/ 1.9 73/ 89/ 99 21/1.9 21 11 ALC OT 
29 Madheswaran 65/M P P A P A 28 0.8 A 140 3.2/2.1 6.4/ 2.1 67/ 58/ 98 45/3.2 24 12 ALC OT 
30 Rajappan 50/M P P A A A 22 0.9 A 142 2/1.2 6.9/ 2.9 58/ 83/ 105 28/ 1.8 16 9 ALC OT 
31 Sadhasivam 62/M P P P A A 26 1.2 P 132 13.8/7.8 6.0/2.0 66/88/299 39/2.3 27 14 ALC D 
32 Karunanithi 60/M P P A A A 18 0.8 A 136 2.8/1 7.2/2.6 22/78/177 23/1.2 12 10 ALC OT 
33 Gunasekar 45/M P P A A A 10 0.6 A 136 4.2/2.5 8.4/2.2 77/49/117 24/1.6 17 10 ALC OT 
34 Suresh  28/M P P A A A 16 0.7 A 137 6/3.6 8.0/2.4 67/88/179 15/1.1 14 10 ALC OT 
35 Krishnamoorthy 80/M P P P P A 15 0.8 A 116 10.3/8.2 8.8/2.1 79/58/121 46/3.4 31 14 ALC D 
36 Ganesan 52/M P P P A A 28 0.9 P 114 10.5/3.5 5.8/2.8 72/59/99 27/1.9 23 11 ALC OT 
37 Elango 45/M A P A A A 26 1 A 140 2.4/1.1 6.6/2.1 88/62/100 22/1.1 11 8 ALC OT 
38 Sakthivel 43/M P P P A A 24 1.2 A 118 8.5/2.2 6.8/2.7 79/82/99 24/1.6 22 11 ALC OT 
39 Mohan 50/M P P A A A 25 0.8 A 143 3.5/2.5 7.0/3.1 99/82/201 38/1.9 18 10 ALC OT 
40 Dhanasekar 30/M P P P A A 18 0.8 P 116 14.6/4.8 7.2/3.6 112/108/23 42/2.6 27 11 ALC OT 
41 Murugesan 60/M P P A A A 32 0.9 p 135 18.6/7.8 8.4/3.9 67/88/99 44/3.1 30 10 ALC OT 
42 Kandhasamy 59/M P P A A A 36 0.7 A 129 15.5/5.6 8.4/3.7 90/69/171 37/2.8 28 10 ALC OT 
43 Raja 42/M P P A P A 37 1.1 A 142 4.5/2.9 8.8/3.7 89/80/170 63/4.3 29 10 ALC OT 
44 Devendiran 40/M p P P A A 38 1.2 P 131 18.5/7.4 7.8/1.9 99/88/94 28-Feb 27 11 ALC OT 
45 chinadurai 50/M p P A A A 39 0.6 A 143 6.5/3.8 7.3/1.4 99/77/164 26/1.8 20 11 ALC OT 
46 Selvam 55/M p P P P P 86 4.3 P 118 8.3/4.2 6.3/1.6 82/76/112 62/3.3 41 14 ALC D 
47 prakash 52/M p P A A A 15 0.8 A 139 2.5/2.9 6.9/2.8 88/48/89 29/1.7 17 10 ALC OT 
48 Lakshmi 48/F p P A A A 16 0.7 A 140 3.9/2.8 8.2/3.1 90/69/136 28-Feb 19 10 ALC OT 
49 Munusamy 28/M p P A A A 35 0.9 A 139 3.9/2.7 5.6/1.5 60/73/177 24/1.4 15 10 ALC OT 
50 Raja 50/M p P P A A 32 1 A 131 10.3/3.1 6.9/2.5 88/37/153 41/2.8 27 13 ALC OT 
 
S.NO NAME AGE/SEX ASCITES PHT HE COAG HRS UREA Cr VB Na TB/DB TP/ALB AST/ALT/ALP PT/INR MELD CPS CAUSE OUTCOME 
51 Gunasekar 45/M p P A A A 34 1.1 A 118 10.3/6.4 8.3/2.9 83/93/162 38/2.4 24 11 ALC OT 
52 Prakasam 61/M p P A A A 36 0.7 P 142 11.6/6.4 7.9/2.4 63/79/141 36/2.5 27 11 ALC OT 
53 Karupannan 46/M p P P A A 39 0.8 P 131 10.3/3.8 6.4/2.0 41/59/111 28/2.1 24 12 ALC OT 
54 Husain 40/M p P P A A 15 0.7 A 133 9.3/6.8 7.3/2.7 83/99/166 26/1.8 21 12 ALC OT 
55 Venu 60/M p P A A A 17 0.8 A 145 5.3/2.5 7.9/3.1 92/88/170 28/2 20 12 ALC OT 
56 Chinnaponu 45/F p P P A A 16 0.8 A 118 11/6.3 8.3/3.0 99/77/132 16/0.8 15 10 HEP B OT 
57 Nagaraj 48/M p P A A A 24 0.9 P 135 9.6/5.4 8.0/2.5 55/67/129 20/1.2 17 10 ALC OT 
58 Murugan 43/M p P P A A 15 1 A 137 2.7/2 7.4/2.9 60/59/89 17/1.5 15 10 ALC OT 
59 Subramani 55/M p P A A A 28 1 A 118 10.6/7.9 7.7/3.6 88/79/102 19/1.8 22 10 ALC OT 
60 Marudhamuthu 45/M p P A A A 15 1.2 A 130 12.6/8.9 6.0/2.1 58/62/104 23/2.0 26 11 ALC OT 
61 Mohan 53/M P P P P P 98 3.6 P 127 14.6/3.8 7.7/3.0 77/84/105 56/3.8 44 14 ALC OT 
62 Asaithambi 40/M A A A A A 25 0.5 A 143 2.2/1.3 7.2/3.6 66/49/91 16/1.1 10 6 ALC OT 
63 Ponnusamy 58/M A P A A A 26 0.9 A 139 1.8/.9 8.3/4.5 88/77/99 12/0.6 9 5 ALC OT 
64 
Mohammad 
mustafa 45/M P P P P A 28 
0.5 
A 117 10.4/3.8 6.1/3.1 81/93/164 50/3.7 30 12 ALC OT 
65 Srinivasan 32/M P P A A A 27 0.4 A 136 5.8/2 6.7/2.5 51/63/79 18/0.9 13 10 ALC OT 
66 Karupannan 17/M P P P A A 19 0.8 P 108 9.3/6.1 6.9/2.8 88/56/158 24/1.2 17 10 ALC OT 
67 Venkatesan 44/M P P A A A 17 0.7 A 131 8.4/4.7 7.3/3.3 57/77/167 26/1.9 22 10 ALC OT 
68 Mohana 44/M P P A A A 18 0.9 P 136 4.3/2.8 7.9/3.5 88/99/159 26/1.9 19 10 ALC OT 
69 Velusamy 47/M P P A A A 39 0.4 A 138 1.6/0.5 7.2/3.8 47/79/153 28/2 16 7 ALC OT 
70 Karnanithi 60/M P P P A A 25 0.8 A 131 12.6/4.6 7.3/4.1 67/79/127 18/0.9 16 9 ALC OT 
71 Krishnamoorthy 50/M P P P A A 26 1 . 2 A 119 7.9/4.9 7.7/3.3 83/64/172 24/1.5 21 10 ALC OT 
72 Sivakumar 43/M P P A A A 27 1.3 P 131 8.6/3.6 7.9/3.5 83/58/163 30/2.2 26 10 ALC OT 
73 Sokkalingam 61/M P P A A A 28 1.1 P 139 9/5.5 8.3/3.0 77/99/105 27/1.9 23 10 ALC OT 
74 Thiyagarajan 57/M P P P A A 37 1 A 132 8.3/3.5 6.4/2.9 58/64/98 29/1.6 20 10 ALC OT 
75 Madheswaran 55/M P P P A A 36 0.8 A 117 9.8/3.2 6.3/2.0 89/48/88 31/1.8 22 12 ALC OT 
 
S.NO NAME AGE/SEX ASCITES PHT HE COAG HRS UREA Cr VB Na TB/DB TP/ALB AST/ALT/ALP PT/INR MELD CPS CAUSE OUTCOME 
76 Arun kumar 36/M P P A A A 28 0.7 A 140 6.3/2.6 6.6/1.9 37/28/98 18/1.6 19 10 ALC OT 
77 Jagan 40/M P P A A A 27 0.4 P 139 4.9/2.5 7.6/1.9 72/59/107 38/1.9 20 11 ALC OT 
78 Mahalingam 32/M P P P A A 12 0.5 A 136 10.4/7.8 6.3/3.3 88/66/167 41/2.7 26 12 ALC OT 
79 Maarichetty 52/M P P A P A 16 0.9 P 116 12.7/7.3 8.3/2..7 67/83/163 60/3.7 31 10 ALC OT 
80 Nali goundar 43/M P P A P A 38 0.8 P 118 16.3/6.6 5.8/2.1 17/29/149 61/1.2 30 12 ALC OT 
81 Palani 44/M P P A A A 19 0.8 A 136 11.3/5.7 6.7/2.0 84/93/163 48/2.6 26 12 ALC OT 
82 Santhappan 57/M P P A A A 28 0.7 A 140 13.5/7.3 7.0/2.4 70/83/157 24/1.6 22 10 ALC OT 
83 Rajeswari 57/M P P A P A 38 0.6 P 132 12.4/8.3 7.2/3.6 67/88/99 72/4.1 32 10 ALC OT 
84 venkatesan 59/M P P A P A 27 1.1 A 142 5.7/3.5 8.4/3.3 80/104/194 68/3.4 28 11 ALC OT 
85 Kumar 52/M P P A A A 28 0.5 P 139 4.2/2.9 7.3/3.2 52/49/173 42/2.8 23 11 ALC OT 
86 Selvam 39/M P P A P A 15 1.1 A 118 13,4/7 6.7/2.5 33/72/138 39/2.5 27 12 ALC OT 
87 Unnamalai 30/M P P A A A 16 1.3 A 138 10.6/4.4 5.8/2.1 22/63/89 20/1.4 22 10 ALC OT 
88 Sakthivel 38/M P P A A A 21 1.2 A 136 7.6/3.6 6.2/2.8 37/49/93 18/1.6 21 9 HEP C OT 
89 Kesavan 45/M P P P A P 90 4.2 A 131 10.6/4.3 6.9/2.3 49/62/168 17/1.6 34 11 ALC OT 
90 Aranganathan 51/M P P A A A 38 0.6 P 138 8.8/2.2 4/2.1 39/82/182 28/1.8 21 11 ALC OT 
91 Selvagounder 50/M P P A A A 22 0.9 A 133 10.6/5.8 8.5/2.8 54/79/170 36/2.1 24 10 ALC OT 
92 Krishnaraj 63/M P P A A A 26 0.4 A 142 5.3/3.8 6.6/2.9 60/77/152 16/1.1 14 9 ALC OT 
93 ravi 55/M P P A A A 31 0.7 A 132 12.4/6.8 7.7/3.0 47/49/99 23/1.6 21 9 ALC OT 
94 Prem kumar 49/M P P A A A 38 0.9 A 141 4.3/3.5 7.9/1.9 84/69/105 21/1.3 15 10 ALC OT 
95 Venkatachalam 60/M P P A A A 15 0.5 P 133 12.2/7.4 5.9/1.4 59/69/169 32/2.2 25 11 ALC OT 
96 Rajendran 46/M P P A P A 19 1.2 A 136 11.6/4.8 7.2/2.9 77/44/181 59/3.3 31 11 ALC OT 
97 Varadharajan 57/M P P P P P 80 3.6 P 125 14.4/3.8 8.4/3.9 31/49/89 60/4.0 44 12 ALC D 
98 Chandra 57/M P P P A P 78 4.3 A 118 18.2/5.8 7.3/2.5 52/49/169 37/2.6 41 13 ALC D 
99 Muniyan 53/M P P P A A 26 0.8 P 129 11.4/5.8 7.6/3.2 28/36/152 27/2.1 24 11 ALC D 
100 Muthugounder 62/M P P A A A 39 0.9 A 138 8.2/6.5 8.3/2.9 46/37/133 25/1.9 22 10 ALC OT 
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KEY TO MASTER CHART 
PHT- PORTAL HYPERTENSION 
HE- HEPATIC ENCEPHALOPATHY 
HRS- HEPATORENAL SYNDROME 
Na- SODIUM 
TB- TOTAL BILIRUBIN 
DB- DIRECT BILIRUBIN 
TP-TOTAL PROTEIN 
ALB- ALBUMIN 
ALT- ALANINE TRNSAMINASE 
AST- ASPARTATE TRANSAMINASE 
ALK- ALKALINE PHOSPHATASE 
PT- PROTHROMBIN TIME 
INR- INTERNATIONAL NORMALISED RATIO 
MELD- MODEL FOR ENDSTAGE LIVER DISEASE 
CPS- CHILD PUGH SCORE 
HEP B-HEPATITIS B 
HEP C-HEPATITIS C 
ALC- ALCOHOL 
OT- ON TREATMENT    D- DEATH 
VB –VARICEAL BLEEDING   A-ABSENT 
COAG- COAGULOPATHY    P-PRESENT 
Cr –CREATININE 
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